Archive for August, 2011

The Detroit Mother Who Refused to Defer to Authority & Drug Her Child—Maryanne Godboldo

Wednesday, August 31st, 2011

Freedom Watch with Charles Payne
Fox Business Channel
August 30, 2011



Transcript:

Charles Payne:  Charges for allegedly shooting at policemen when they came to take way her daughter. The department of human services issued an order because she took her daughter off an antipsychotic medication. Godbolbo denied ever firing a weapon.  A judge dismissed the criminal charge yesterday saying there was no evidence to support them and agreeing with Godboldo’s lawyers that child services order was invalid.

Here to discuss this case from is the President of the Future of Freedom Foundation, Jacob Hornberger.

Jacob, I almost don’t know where to begin on this. You know first and foremost this kid is on an antipsychotic medication the mother obviously doesn’t want that to happen. Secondly the police come and try to forcibly take away the child. Help us understand this case.

Jacob Hornberger: Yeah, it’s an act… it’s a remarkable model of of how a parent will react when the state is trying to do something that the parent thinks is harmful to the children. This woman refused to defer to authority.  It’s something that a lot of parents would never think about doing. The cops show up, they’ve got a court order commanding the woman to relinquish her 13-year-old little girl for the purpose of injecting mind-altering drugs into this child. The mother says “no I’m taking her of this junk, she’s not going to go on it and you’re not going to take her away,” and she barricades herself in her house and she says the cops aren’t going to do this. Well the cops ultimately charge this woman with resisting arrest, firing a weapon at them, barricading in her house, and refusing to obey this court order.  The thing goes to court and it turns out the cops where there with an invalid court order, they didn’t even have the Judges signature on the court order. They’d gotten the clerk to just stamp the Judge’s signature on it. The Judge throws the charges out, he dismisses the gun charges, says she never fired a weapon at the police. But really it’s a model of how parents should not defer to authority under any circumstance. But especially when your child’s welfare is at stake.

Charles: Jacob it could also be a model of just how arrogant government at all levels has become and many case the police are just following a lock step with this, just thinking, “hey, I can get someone to just stamp this, this women probably doesn’t know her rights, she’ll probably hand over the kid and we’ll have, you know, all in a days work.”

Jacob: Absolutely. This is what goes on in totalitarian countries, this is what went on in the form soviet union, this is what went on in fascist Italy, this is what goes on in Burma. The police operate effectively as thugs and they are in there saying, “we don’t need to follow the law, we don’t need to follow the procedures that are established by the law, we’re gonna just come over here and seize this child because we’ve got the guns,” and this mother said “oh no you’re not gonna do that.” And the other thing, you notice Charles you know, that the Government has been waging this 30-year-old fail war on drugs and they won’t let it go, yet here they are the purveyors of drugs. They’re trying to inject these mind-altering substances in this little girl just like they do in many of the public schools, where they, where they, a kid resists authority [Charles: right] he’s bored with schools they put him on Adderall, Ritalin, they screw up his life for the rest of his life, because he did not defer to their authority in these government schools.

Charles: Jacob I say amen to that. We have over-medicated our kids and taken away all kinds of parental responsibilities. We’ve got a couple of seconds left. The ultimate message here for parents watching this show, is stand your ground, defend yourself, even when its against a big, big government that looks like you can’t beat, you know the old saying, you can’t beat city hall.

Jacob: Absolutely, and especially when they welfare of your children are concerned, that’s the for most importance not deferring to what you think the state knows about what’s best for your child or your family.

Charles: Jacob thanks very much, we appreciate it. That’s a message we needed to hear tonight. Appreciate it.

Jacob: Thank you.

« Return to news items


Share

Judge dismisses charges against Detroit mom accused of firing at officers coming to take her daughter

Wednesday, August 31st, 2011

Godboldo was accused of firing a gun at police who had accompanied Child Protective Services who had a Court order to take Godboldo's 13-year-old daughter after Godboldo had been accused of discontinuing a psychotropic drug. Godboldo maintained she had the right to decide her daughter's medical treatment.

In a case that sparked debate about parental rights versus state involvement in the medical care of children, a Detroit woman won a major victory Monday when all the charges against her were dropped.

Maryanne Godboldo, 57, was accused of firing a gun at Detroit police officers who were assisting a state Child Protective Services worker when they came to her Blaine Street home on March 24 to get her daughter.

The charges against Godboldo were dismissed at her preliminary examination in 36th District Court in Detroit. Judge Ronald Giles agreed with her lawyers that the court order to remove Godboldo’s 13-year-old daughter was not valid.

“I am very, very happy and blessed that Judge Giles did the right thing,” Godboldo said at a news conference at Hartford Memorial Baptist Church in Detroit.

Giles also agreed that there was no evidence supporting the charge that Godboldo fired a gun at police during the standoff.

When asked about Giles’ ruling, Detroit Police Sgt. Eren Stephens said: “Ms. Godboldo was afforded her due process under the law. We abide by and respect the decision.”

Maria Miller, spokeswoman for the Wayne County Prosecutor’s Office, said the prosecutor will appeal the dismissal of charges.

Godboldo legal team confident that case will survive an appeal

Maryanne Godboldo’s legal team is confident that a Wayne County District Court judge’s dismissal of all charges against her on Monday will survive an appeal.

“The standard is abuse of discretion,” said Byron Pitts, one of Godboldo’s lawyers. “The court today did not abuse his discretion.”

Godboldo, 57, of Detroit was charged with discharge of a weapon, three counts of felonious assault, resisting and obstructing an officer and felony firearm.

She was accused of firing a gun at police who had accompanied a state Child Protective Services employee to Godboldo’s home on Blaine on March 24.

The employee had a Juvenile Court order to take Godboldo’s 13-year-old daughter after Godboldo had been accused of neglecting her by discontinuing a psychotropic drug. Godboldo has maintained she has the right to decide her daughter’s medical treatment.

Police said Godboldo barricaded herself in her home with her daughter and shot at them.

After hearing testimony at Godboldo’s preliminary examination in 36th District Court on Monday in Detroit, Judge Ronald Giles ruled that the court order was not valid and that there was insufficient evidence that Godboldo fired at police officers.

Maria Miller, spokeswoman for the Prosecutor’s Office, said the dismissed charges will be appealed. Miller said that Wayne County Circuit Judge Lynne Pierce earlier determined at a Juvenile Court hearing that the order to remove the child was valid.

The appeal will be heard in Wayne County Circuit Court.

At a news conference Monday at Hartford Memorial Baptist Church, Pitts and Godboldo’s other attorney, Allison Folmar, explained why they prevailed.

Folmar said Godboldo “never shot at an officer — period. It never happened.”

They said the court order was not valid because a court clerk stamped the judge’s name to the order without consulting the judge.

“A judge never looked at this, never saw it,” Pitts said. “It has to be an elected authority. This lady took the judge’s stamp, stamped the judge’s name and off she goes.”

He called it “a huge constitutional error.”

As a result of this case, Pitts said, there has been a policy change. Court employees are no longer allowed to stamp judges’ names on court orders.

Godboldo’s supporters say Giles’ ruling was justice.

Sandra Hines, a member of the Godboldo Action Committee, said: “This case is rooted on the grounds of parental rights. It’s the right of every parent to be the custodial caregiver over their child.”

Ron Scott of the Detroit Coalition Against Police Brutality, said, “It’s a victory for parental rights.”

He also said that “Citizens have the right not to adhere to questionable reasons for entering their home. A person does not have to allow an unreasonable search and seizure to their home.”

Neema Yacen of Detroit and a member of the Godboldo Action Committee, said it was a case of state overreach. “This is a mother who said her child had a problem, took her to the people who she thought could help her, and they crucified her.”

Godboldo, whose daughter is now in the custody of her sister Penny Godboldo, is working to get her child back.

Judge Pierce has said she needs to evaluate the girl’s current treatment and is seeking a report from her doctor.

http://www.freep.com/article/20110830/NEWS02/108300383/Detroit-mom-cleared-charges-stemmed-from-standoff-home

« Return to news items


Share

Big pharma pays US doctors $150m in 2011

Tuesday, August 30th, 2011

PMLive
August 30, 2011

A report by the Financial Times has claimed a group of pharmaceutical companies has paid doctors in the US almost $150m so far during 2011.

Prepared in conjunction with the data provider, PharmaShine, the figures show the money was paid by pharmaceutical firms, including Eli Lilly, AstraZeneca (AZ) and Pfizer, for doctors’ travel and entertainment expenses as well as education and consultancy fees.

Of those companies who have released data, Lilly is reported to have paid $48m and Pfizer to have paid $42m.

AZ, who recently launched a database containing payments made to doctors and institutions, said $24.7m was paid out in associated compensation for the second quarter of 2011, with $8.1m going to individual physicians and $16.6m going to institutions.

In a post on the company’s AZ Health Connections blog, US compliance officer, Marie Martino, gave reason as to why the company was releasing its data.

She said: “AstraZeneca believes it is important to be open about how we conduct our business, and this new reporting expands on a major initiative announced three years ago to provide greater public visibility into how we do business.”

Around 165,000 doctors have received related payments in 2011 so far, compared to 262,000 doctors who received payment in 2010.

The report comes at a time when US government agencies are preparing guidelines to make the publication of industry support for medical professionals compulsory by 2013.

This is part of ongoing US healthcare reforms as an attempt to allow better, more consistent understanding of the pharmaceutical industry’s relationship with healthcare professionals in the US.

In the UK, the Association of the British Pharmaceutical Industry (ABPI) changed its code of practice at the beginning of 2011 to help increase transparency of working practices between the pharmaceutical industry and healthcare professionals to help increase trust.

Companies will have to declare payments to healthcare professionals for services including speaker fees, advisory boards and consultancy, and sponsorship for attendance at meetings on an annual basis. The first declaration will be made in 2013 for payments made in 2012.

http://www.pmlive.com/find_an_article/allarticles/categories/General/2011/august_2011/news/big_pharma_pays_us_doctors_$150m_in_2011

« Return to news items


Share

CCHR exposes list of psycho-pharma front groups

Monday, August 29th, 2011

Natural News
By PF Louis
August 29, 2011

A highly effective public relations technique is the “third party technique” of creating front groups to endorse or promote the need of any service or product. The first party is the original group or client that would benefit more from increased public trust or affinity. The second group is the public or consumers. A third group is created with a contrived name to appear publicly as a disinterested party endorsing the industry of the first party.

Often, the third party, or front group, uses a name that implies authority or concern for the public’s welfare or concerns. You can be sure these bogus front groups are usually only concerned about their clients welfare and themselves.

Edward Bernays Pioneered Front Groups

Edward Bernays, a notorious spin doctor throughout the 20th Century, is considered USA’s original front group creator as well as the father of public relations. The public relations industry is concerned with creating a favorable image more than direct sales advertising, although they can be closely associated at times.

The womens rights movement peaked in 1919 with the passage of the 19th amendment, granting women the right to vote. A very few years later, Edward Bernays created an image to help promote the tobacco industry. He had photographs published in newspapers and magazines of several women marching in a New York City Easter parade brazenly smoking cigarettes, which until then was considered unladylike. The idea was to link a womans struggle for more rights with openly smoking anywhere, just like the guys.

Besides making tobacco appear healthy over several years using fake doctors to promote various cigarette brands, Bernays also used front groups to glorify fluoridating water supplies. He was a very important contributor to our mass poisoning.

Psychiatry, Big Pharma, and Front Groups

The Citizens Commission on Human Rights International (CCHRI) focuses on psychiatry’s irrational and barbaric treatment of mental illness with its propensity for categorizing behavior in order to dispense harmful drugs. It’s a cozy arrangement with the American Psychiatric Association (APA) and Big Pharma.

Ever since the APA was accepted as a regular medical organization a few decades ago, Big Pharma’s sales for psychotropic drugs have gone through the roof. What was once pen and pad for taking notes by a psychiatrist during talk therapy became the pen and prescription pad.

For children, psychiatry’s categorizing behavioral problems enables educational and child care institutional personnel virtual prescription power as well. Children are kidnapped “legally” by social services agencies if parents refuse to medicate them according to psychiatric decree. Big Pharma’s reach into TV advertising enables depressed adults to demand prescriptions for drugs that lead to bad health, actual insanity, and death.

Front groups exposed by CCHRI include the following: The National Alliance on Mental Illness (NAMI), Children and Adults with Attention Deficit Hyperactivity Disorder (CHAAD) and several bipolar, depression or ADHD “support groups” that flourish on the internet.

CCHRI has several more front groups listed on one of their site pages with links to explanations of who they really are and how they function for psychiatry and Big Pharma. (see CCHRI source below)

CCHRI’s depth of investigative reporting offers the premier site for understanding the true nature of psychiatry and its relationship with Big Pharma’s destructive psychotropic drug racket.

Front Groups Everywhere

Front groups can also lobby directly to government officials, elected or appointed. And they are created for almost any controversial issue that needs to be white or green washed.

A former health insurance insider, Wendell Potter, became a whistle blower with his book Deadly Spin. He explained that a front group “Health Care America” was used to attack Michael Moore’s “Sicko” documentary.

APCO Worldwide created Health Care America with Big Pharma money. The insurance industry used APCO in 2007. APCO recruits think tanks and other agencies as allies for their campaigns. The public is unaware of who is really supplying the media’s information.

Earlier in 2011, New York Republican Congresswoman Nan Hayworth submitted a press release photo of her receiving a plaque from a representative of a purported senior citizen support group called 60 Plus Association. The sign above those two declared in large letters “Senor Citizens Thank You for Protecting Medicare and Social Security.”

There are two lies here. Nan Hayworth had voted against Medicare, and 60 Plus has hardly any senior citizen members at all. They remain afloat financially from Big Pharma’s funding, according to AARP.

All this crassly corrupt activity backed by government and corporations continues to escalate through the mainstream media. A lyric from a 1980s jazz tune rings true “We are Caught in a Blizzard of Lies.” The upside is we are forced to distinguish between truth and fiction and become our own informed authority.

Sources for this article include:

List of Front Groups for Psychiatry and Big Pharma http://www.cchrint.org/psycho-pharm…

Main page CCHRI site http://www.cchrint.org/

Insurance whistle blower Wendell Potter http://www.commondreams.org/view/20…

60s Plus Group outed by AARP as Big Pharma front group http://my.firedoglake.com/junkyardd…

Edward Bernays pioneered third party technique of PR and advertising http://www.frontgroups.org/node/418

« Return to news items


Share

Antidepressant tied to heart risk

Friday, August 26th, 2011

Health24
August 25, 2011

High doses of the popular antidepressant Celexa (known as Cipramil in South Africa) can cause potentially fatal abnormal heart rhythms and should no longer be prescribed to patients, the US Food and Drug Administration has said.

Doses of Celexa (citalopram hydrobromide) greater than 40 milligrams a day can cause changes in the electrical activity of the heart, which can lead to abnormal heart rhythms, including a potentially deadly arrhythmia known as Torsade de Pointes, according to the agency.

Patients at high risk for changes in the electrical activity of the heart include those with pre-existing heart conditions (including congestive heart failure) and those prone to low levels of potassium and magnesium in the blood, the FDA said.

Read entire article:  http://www.health24.com/news/Depression/1-903,65865.asp

« Return to news items


Share

US health agency revises conflict of interest rules

Tuesday, August 23rd, 2011

From Project on Government Oversight:

In recent years, Senator Grassley exposed several academic physicians for taking large amounts of money from companies with a direct financial interest in their research, some of it funded by the NIH. The list reads like a who’s who in academic research:

    • Dr. Charlie Nemeroff, former Chair of the Psychiatry Department at Emory University, who failed to report hundreds of thousands of dollars in payments from GlaxoSmithKline while researching that same company’s drugs with an NIH grant.  Dr. Nemeroff was bounced from Emory and has now taken over the Chair of Psychiatry at the University of Miami.
    • Dr. Alan Schatzberg, former Chair of the Psychiatry Department at Stanford University received an NIH grant to study a drug while partially owning a company that was seeking FDA approval of said drug. An NIH oversight group recommended that Stanford’s clinical trial on mifepristone be “terminated immediately and permanently.”  The recommendation was made because of concerns over conflicts of interest, patient safety and other issues.
    • Dr. Joseph Biederman and two other researchers at Harvard University failed to report almost a million dollars each in outside income while heading up several NIH grants. Harvard later disciplined the three physicians.

US health agency revises conflict of interest rules

From Reuters – August 23 – 2011

by  Alina Selyukh

WASHINGTON,  – The U.S. National Institutes of Health revised on Tuesday its 16-year-old conflict of interest rules for medical researchers, lowering the amount of money that constitutes a financial conflict and expanding the required disclosures.

The 1995 regulations effectively put responsibility for tracking scientists’ financial conflicts of interest on their universities. The rule required researchers to disclose conflicts to their institutions, which then had to assure the NIH the conflict had been managed, reduced or eliminated.

The new rule extends that requirement so researchers report not only the fact of a conflict of interest, but also its details such as value, specific nature, why it is a conflict and the impact it might have on research.

It lowers the amount a researcher must disclose if received from an industry or held in company stock to $5,000 from about $10,000.

Research institutions, in turn, are now required to report that information to the federal grant-awarding agency alongside details of how the conflicts are managed. Also, before spending any grant money, the institution has to post information about the financial conflicts on a public website.

The new rules will affect about 2,000 organizations that are awarded public health science funding every year and some 38,000 scientists who participate in research funded by these grants and have a “significant financial interest,” NIH said.

Concern about the integrity of research in the United States has grown since 2008, when Iowa Republican Sen. Charles Grassley criticized prominent Harvard University psychiatrist Dr. Joseph Biederman and others for failing to fully disclose payments from drug companies.

In a more recent example, medical device maker Medtronic Inc (MDT.N) came under fire over accusations that doctors paid by the company had failed to disclose major side effects from a bone growth drug in clinical trials.

A 2009 report by the Institute of Medicine, one of the National Academies of Sciences that advises U.S. policymakers, called on doctors to strictly disclose research funding to strengthen protection against conflicts of interest. The report called for virtually anyone involved in medicine — academic medical centers, journals, professional societies, researchers and doctors — to set up or strengthen conflict of interest guidelines.

From 1996 to 2007, relationships between individual academic researchers and industry nearly doubled, according to a study cited by NIH in its final rule. From 1994 to 2003, the amount of financial support for biomedical research almost tripled to $94.3 billion, with 57 percent of that funding coming from industry sources, according to analysis cited by NIH. (Additional reporting by Anna Yukhananov; editing by Andre Grenon)

http://www.reuters.com/article/2011/08/23/health-science-conflicts-idUSN1E77M1PB20110823

 

« Return to news items


Share

Why Drug Companies Are Shy About Sharing On Facebook

Tuesday, August 23rd, 2011

NPR – August 22, 2011
by Nancy Shute

Drug firms fear that being "liked" on Facebook could get them in trouble with the FDA. iStock photo

People love how Facebooklets them comment on and share other people’s posts. But the idea of sharing on social media has got drug companies scared. When Facebook told drugmakers that they had to start allowing comments on their Facebook pages, some of those pages started disappearing.

“Take On Depression” suddenly disappeared. “ADHD Moms” vanished, too. So did “Epilepsy Advocate.” In the past, drug companies had been reluctant to create Facebook pages without a guarantee that they’d be closed to public comments — a unique accommodation on Facebook’s part. But that accommodation ended last week.

Diabetes blogger Amy Tenderichthinks it’s high time the drug companies quit walling themselves off. She’s the founder of  Diabetest Mine,  an independent site. She says: “The notion that they would be able to be able to put up these Facebook pages and then close them off to comments is ridiculous.”

On her site, people with diabetes comment a lot. They share information on what drugs they’re taking, give each other advices on dosages, and tell people which drugs are working for them, and which are causing side effects. For Tenderich and others, the whole point of social media like Facebook and Twitter is to comment on other people’s posts.

But drug companies have to play by different rules. The Food and Drug Administration requires that each a drug manufacturer mentions a prescription drug, they also have to list its risks and side effects. That’s called fair balance.

“You see some of those magazine ads that are three and four pages long and you wonder why they are?” asks Tony Jewell, who supervises drugmaker AstraZeneca’s social media efforts. “It’s because we’re communicating the full risks, benefits and appropriate use of the medicine. That’s a little bit harder to do in a social media channel like Facebook and Twitter.”

One big reason companies cite for killing Facebook pages is that they wouldn’t be able to adequately police comments with inaccurate information about prescription drugs.

“So they might say, ‘Lipitor’s great at whitening your teeth,’ which it’s not approved to do,” says Jonathan Richman. That’s his example of a potentially dicey comment. He’s a group director for the Possible Worldwide ad agency in Cincinnati, and he closely follows the drug industry’s social media efforts on his Dose of Digital blog. “The question becomes, What’s Pfizer’s liability? What action could the FDA take, based on somebody else posting that?”

So far, the FDA hasn’t come down on a single drug company for allowing public comments. The only action the agency has taken against use of social media was last year, when it warnedNovartis that a Facebook “share” widget for the leukemia drug Tasignaviolated fair balance.

But the FDA also hasn’t told the companies how to use social media and still follow the “fair balance” rule. In November 2009, the agency held public hearingson how pharma companies should use social media. But the FDA has yet to issue official guidance. Jewell says that because of that, his employer and other companies are erring on the side of caution.

Tenderich says patients would benefit from a rich interaction with drug makers. She sees more and more drug company employees interacting on her site, giving advice on behalf of their employers. That’s a huge benefit for patients, she says.

The pharmaceutical companies could benefit, too, she says, by learning what problems patients are having with drugs, and how to make them better.

“They could get so much fantastic, free, very high-value feedback,” she says.

http://www.npr.org/blogs/health/2011/08/22/139859210/why-drug-companies-are-shy-about-sharing-on-facebook?ps=sh_sthdl

« Return to news items


Share

Ron Paul Reintroduces The Parental Consent Act 2011- Prohibits Federal Funding For Psychiatric ‘Screening’ of Kids

Monday, August 22nd, 2011

Congressman Ron Paul has re-introduced  The Parental Consent Act ,  A bill which prohibits federal funds from being used to establish or implement any universal or mandatory mental health, psychiatric, or socioemotional screening program.

“Many children have suffered harmful side effects from using psychotropic drugs. Some of the possible side effects include mania, violence, dependence and weight gain. Yet, parents are already being threatened with child abuse charges if they resist efforts to drug their children. Imagine how much easier it will be to drug children against their parents’ wishes if a federally-funded mental-health screener makes the recommendation.” – RON PAUL

Sign the petition in support of the Parental Consent Act here: http://www.petitiononline.com/rppca/petition.html

Bill information:  The Parental Consent Act 2011 (H.R. 2769 – previously H.R. 2218  in 2009) Prohibits federal education funds from being used to pay any local educational agency or other instrument of government that uses the refusal of a parent or legal guardian to provide consent to mental health screening as the basis of a charge of child abuse, child neglect, medical neglect, or education neglect until the agency or instrument demonstrates that it is no longer using such refusal as a basis of such charge.

Defines a screening program under this Act as any mental health screening program in which a set of individuals is automatically screened without regard to whether there was a prior indication of a need for mental health treatment, including: (1) any program of state incentive grants to implement recommendations in the July 2003 report of the New Freedom Commission on Mental Health, the State Early Childhood Comprehensive System, grants for TeenScreen, and the Foundations for Learning Grants; and (2) any student mental health screening program that allows mental health screening of individuals under 18 years of age without the express, written, voluntary, informed consent of the parent or legal guardian of the individual involved.

Ron Paul speech given on April 30, 2009 on his bill, The Parental Consent Act (formerly H.R. 2218, now  reintroduced as H.R. 2769 ):

Madam Speaker, I rise to introduce the Parental Consent Act. This bill forbids Federal funds from being used for any universal or mandatory mental-health screening of students without the express, written, voluntary, informed consent of their parents or legal guardians. This bill protects the fundamental right of parents to direct and control the upbringing and education of their children.

The New Freedom Commission on Mental Health has recommended that the federal and state governments work toward the implementation of a comprehensive system of mental-health screening for all Americans. The commission recommends that universal or mandatory mental-health screening first be implemented in public schools as a prelude to expanding it to the general public. However, neither the commission’s report nor any related mental-health screening proposal requires parental consent before a child is subjected to mental-health screening. Federally-funded universal or mandatory mental-health screening in schools without parental consent could lead to labeling more children as “ADD” or “hyperactive” and thus force more children to take psychotropic drugs, such as Ritalin, against their parents’ wishes.

Already, too many children are suffering from being prescribed psychotropic drugs for nothing more than children’s typical rambunctious behavior. According to Medco Health Solutions, more than 2.2 million children are receiving more than one psychotropic drug at one time. In fact, according to Medico Trends, in 2003, total spending on psychiatric drugs for children exceeded spending on antibiotics or asthma medication.

Many children have suffered harmful side effects from using psychotropic drugs. Some of the possible side effects include mania, violence, dependence, and weight gain. Yet, parents are already being threatened with child abuse charges if they resist efforts to drug their children. Imagine how much easier it will be to drug children against their parents’ wishes if a federally-funded mental-health screener makes the recommendation.

Universal or mandatory mental-health screening could also provide a justification for stigmatizing children from families that support traditional values. Even the authors of mental-health diagnosis manuals admit that mental-health diagnoses are subjective and based on social constructions. Therefore, it is all too easy for a psychiatrist to label a person’s disagreement with the psychiatrist’s political beliefs a mental disorder. For example, a federally-funded school violence prevention program lists “intolerance” as a mental problem that may lead to school violence. Because “intolerance” is often a code word for believing in traditional values, children who share their parents’ values could be labeled as having mental problems and a risk of causing violence. If the mandatory mental-health screening program applies to adults, everyone who believes in traditional values could have his or her beliefs stigmatized as a sign of a mental disorder. Taxpayer dollars should not support programs that may label those who adhere to traditional values as having a “mental disorder.”

Madam Speaker, universal or mandatory mental-health screening threatens to undermine parents’ right to raise their children as the parents see fit. Forced mental-health screening could also endanger the health of children by leading to more children being improperly placed on psychotropic drugs, such as Ritalin, or stigmatized as “mentally ill” or a risk of causing violence because they adhere to traditional values. Congress has a responsibility to the nation’s parents and children to stop this from happening. I, therefore, urge my colleagues to cosponsor the Parental Consent Act.

For more information on the Parental Consent Act watch this video featuring Kent Snyder, Ron Paul’s Presidential campaign manager 2008, and former Executive Director of the Liberty Committee  http://www.cchrint.org/videos/experts/ron-pauls-parental-consent-act-of-2009/

RETURN TO BLOGS PAGE


Share

Big pharma discredited by Twitter drug-pushing: Not supposed to punt prescription stuff to the public

Monday, August 22nd, 2011

United Kingdom – The Register – August 22, 2011

By OUT-LAW.COM

A pharmaceutical company’s use of Twitter to promote medicines discredited the industry, a regulatory body has ruled.

The Prescription Medicines Code of Practice Authority (PMCPA) said that Bayer Healthcare had violated the Association of the British Pharmaceutical Industry Code of Conduct (ABPI Code). The Code sets rules on what companies can say when informing the public about prescription-only medicines.

Bayer was in breach of the parts of the Code which prohibits the advertising of prescription-only medicines to the public, the PMCPA said. The company also breached a rule that prohibits companies releasing information about prescription-only medicines that would encourage the public to ask their doctor for the product. Bayer also failed to maintain high standards and brought discredit upon, and reduced the confidence in, the pharmaceutical industry – two other rules written into the Code.

An advertisement publicising Bayer’s case was published in The Nursing Standard on 17 August. Further adverts will run in the British Medical Journal and The Pharmaceutical Journal on 20 August.

The PMCPA rules state that it must advertise brief details of all cases where companies bring discredit upon and reduce confidence in the pharmaceutical industry, or when companies are forced to issue a corrective statement or are the subject of a public reprimand.

Last year Bayer copied headlines from press releases it had formed about the launch of two products and sent them out as two tweets to its Twitter followers, according to the PMCPA ruling (3-page/42KB PDF). One of the tweets did not name the product but “referred to its qualities, indication and launch”, while the other tweet “mentioned the brand name, indication and launch”, the PMCPA said.

“The Panel considered that each tweet was in fact a public announcement about the launch of a prescription-only medicine which promoted that medicine to the public and would encourage members of the public to ask their health professionals to prescribe it,” the PMCPA said in its case summary.

“Breaches of the Code were ruled in relation to each tweet as acknowledged by Bayer. The Panel considered that high standards had not been maintained,” the summary said.

“The Panel was concerned that material placed on Twitter had not been certified. That the original press releases were certified was insufficient in this regard. If part of a certified document was reproduced in a different format or directed to a different audience the new material should be certified separately. The Panel was extremely concerned that controls within the company were such that uncertified information about the launch of prescription-only medicines had been posted on Twitter. A breach of [The Code] was ruled,” the summary said.

The self-regulatory Code sets out rules based on compliance with UK laws, including The Medicines (Advertising) Regulations 1994. The regulations were introduced in the UK to implement an EU Directive, the “Community code” relating to medicinal products for human use. Civil and criminal sanctions exist for serious breaches of the regulations.

“Pharmaceutical companies must comply with the ABPI code of practice and have in place sufficient checks and regulations to ensure that breaches of the code such as this do not occur,” Camilla Balleny, legal expert in life sciences at Pinsent Masons said.

“Digital media is moving at such a pace that companies must be on the look out for ways in which issues such as this might breach the code in way not previously envisaged,” Balleny said.

“It seems that the problem in this case arose because of extracts from ‘approved’ announcements of the launch of two new medicines being posted on Twitter in circumstances where Bayer could not verify that the only people who could access the extract were healthcare professionals. The extracts were such that they were considered to be advertising, and in particular, likely to encourage members of the public to ask their health professional to prescribe a specific prescription. Advertising to healthcare professionals is not restricted per se, although the content of such advertisements is still heavily scrutinised for balance and truth,” Balleny said.

In April this year the PMCPA released guidance notes on how companies could use digital media without falling foul of the ABPI Code. Balleny said that inconsistencies exist in global rules governing the advertising of medicines, which makes it difficult for pharmaceutical companies that make information available online.

“In the US the advertising of medicines to the public is permitted. This is in contrast to the restrictions in Europe. This difference has long been a problem for pharmaceutical companies looking to develop website content which reaches around the world and it has led to, for example, the development of healthcare professionals-only websites,” Balleny said.

“Based on the recent PMCPA guidance, if pharmaceutical companies wish to use Twitter from a UK perspective, there is going to need to be tighter restriction on the content, in circumstances where the identity of the signatory cannot be verified,” Balleny said.

http://www.theregister.co.uk/2011/08/22/twitter_advertising_of_medicines_discredited_industry_says_regulator/

« Return to news items


Share

Australian Psychiatrist Patrick McGorry Aborts Controversial Antipsychotic Drug Trial on Kids Amid Protests

Saturday, August 20th, 2011

Drug Trial Scrapped Amid Outcry

The Age
By Jill Stark
August 21, 2011

FORMER Australian of the Year Patrick McGorry has aborted a controversial trial of antipsychotic drugs on children as young as 15 who are “at risk” of psychosis, amid complaints the study was unethical.

The Sunday Age can reveal 13 local and international experts lodged a formal complaint calling for the trial not to go ahead due to concerns children who had not yet been diagnosed with a psychotic illness would be unnecessarily given drugs with potentially dangerous side effects.

Quetiapine, sold as Seroquel, has been linked to weight gain and its manufacturer AstraZeneca, which was to fund the trial, last month paid $US647 million ($A623 million) to settle a lawsuit in the US, alleging there was insufficient warning the drug may cause diabetes.

Professor McGorry, one of the Prime Minister’s key mental health advisers, planned to conduct the trial at Orygen Youth Health in Parkville, listing it on the Australian New Zealand Clinical Trials Registry last March. It was to investigate whether the drug would decrease or delay the risk of people aged between 15 and 40 with early signs of mental illness developing a psychotic disorder such as schizophrenia.

Last month, psychiatrists, psychologists and researchers from Australia, Britain and the US lodged a complaint with the ethics committee of Melbourne Health, the umbrella health service that includes Orygen.

They argued there was little evidence onset of psychosis can be prevented and it was potentially dangerous to use antipsychotics on people who merely have risk factors for a psychotic illness. They said there was evidence that up to 80 per cent would never develop a disorder.

Professor McGorry insists the decision to scrap the trial was made in June and is unrelated to the complaint, which he said he was only alerted to just over a week ago.

He maintained the trial received ethics approval in July last year but was abandoned due to “feasibility issues” with recruiting participants in European and American sites, which were to form the international arm of the study. He said Orygen had to choose between investing in the drug trial or pursuing another trial using fish oil, which had proven to be useful as an early intervention treatment for schizophrenia in a smaller study. He opted for fish oil because it had less potential for side effects than antipsychotics.

Melbourne Health confirmed the complaint will still be considered by its research ethics committee in September. Yesterday the trial was listed as “prospective” on the clinical trials registry but Professor McGorry said it was being removed.

Earlier this month The Sunday Age revealed a growing backlash against the government’s mental health reforms, with Professor McGorry’s peers claiming his youth early intervention model had been “massively oversold”.

Associate Professor Geoff Stuart of La Trobe University’s school of psychological sciences, who signed the complaint, said questions remained about the trial.

“If these feasibility obstacles can be overcome in future [would] Professor McGorry embark on such a trial again? He was willing to endorse a trial which was exploring the use of antipsychotic medication in an at-risk group. There’s a major ethical issue about medicating four people to supposedly save the fifth when you’re not saving them anyway, you’re just masking their symptoms. We’re talking about kids as young as 15 who could get a full dose of antipsychotics and they’re not psychotic.”

Professor McGorry acknowledged the evidence suggested antipsychotics were not effective as a first-line treatment for the at-risk group. But he said the risks had been exaggerated and he would consider a similar trial on patients for whom other treatments had failed. “I wrote the guidelines which said do not use antipsychotics in ultra-high risk patients, so I’ve never been supportive of it in clinical practice … [but] we should have the freedom to research all available options for this population,” he said.

The controversy over the aborted trial largely centres on “psychosis risk syndrome”, a condition that some mental health advocates want formally recognised. But critics say that could lead to young people being wrongly labelled, stigmatised and medicated for symptoms that may be temporary. They also fear that while Professor McGorry says his Early Psychosis Prevention and Intervention Centres prescribe drugs only to those who have experienced a psychotic episode, his willingness to medicate an at-risk group could mean the criteria will broaden. Professor McGorry insists this will not happen.

Early intervention What is it?

EARLY intervention is based on identifying and treating psychosis in its early stages to prevent patients developing full-blown psychotic illnesses such as schizophrenia.

Patrick McGorry’s Early Psychosis Prevention and Intervention Centres (EPPIC) treat young people who have experienced a psychotic episode with treatments such as psychotherapy, family therapy, medication or a combination. He says early treatment significantly improves the chance of recovery and reduces long-term impairment. But diagnosing psychotic disorders is difficult and McGorry’s critics say there is no reliable diagnostic tool to predict if someone will develop a psychotic illness and there is insufficient evidence intervention can prevent it.

Critics say up to 80 per cent of those with ”psychosis risk syndrome” – which refers to people who only have risk factors such as a family history or a deterioration in mental health – never develop an illness. They fear early intervention will lead to many patients being wrongly labelled as psychotic and medicated unnecessarily.

A recently released literature review by The Cochrane Collaboration found there was insufficient evidence that early intervention could prevent psychosis and that any benefits were not long term. Professor McGorry said it used flawed methodology.

http://www.theage.com.au/national/drug-trial-scrapped-amid-outcry-20110820-1j3vy.html?from=age_sb

August 21, 2011

« Return to news items


Share